Oruka Therapeutics
ORKA
14 hedge funds and large institutions have $29.7M invested in Oruka Therapeutics in 2015 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 10 closing their positions.
26% less funds holding
Funds holding: 19 → 14 (-5)
29% less capital invested
Capital invested by funds: $41.7M → $29.7M (-$12.1M)
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$5.72M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$157K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$73.1K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$71.6K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$59.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$653K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$653K |
| 3 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
-$68K |
| 4 |
California Public Employees Retirement System
Sacramento,
California
|
-$66K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
-$38K |
ORKA Hedge Fund Activity: Q3 2015 in Review
14 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q3 2015, worth a combined $29.7M — down 29% from $41.7M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ORKA and 5 opened new positions — a net loss of 5 holders — while 0 trimmed existing stakes and 2 added.
The largest buyer was Tekla Capital Management, opening a new position worth an estimated $5.72M. The largest seller was DAFNA Capital Management, exiting entirely with an estimated $653K sold.
- 14 institutional investors held Oruka Therapeutics (ORKA) as of Q3 2015, down from 19 in Q2 2015.
- Funds reported $29.7M of Oruka Therapeutics stock for Q3 2015, down 29% quarter-over-quarter.
- 5 funds opened new Oruka Therapeutics positions in Q3 2015 and 10 closed out, a net change of -5 holders.
- The largest Oruka Therapeutics buyer in Q3 2015 was Tekla Capital Management, an estimated $5.72M added.
- The largest Oruka Therapeutics seller in Q3 2015 was DAFNA Capital Management, an estimated $653K sold.
Based on aggregated 13F filings for Q3 2015.